CXCR4 and neoplasm: LY2510924 was also activeagainst in vivo NHL xenograft models, in which asignificant dose-dependent tumor growth reduction compared with thevehicle group and a fairly good pharmacokinetic profile were observed.30 Structural modeling analysis suggested thatthe main ligand–receptor interactions of LY2510924 are formedbetween its naphthalene and hydroxy benzene with the CXCR4 residuesAsp187, Arg188, Gln200, His113, and Tyr190.